Zestril
Zestril Price range: $ 41,00 through $ 210,00
Back to products
Zhewitra
Zhewitra Price range: $ 28,00 through $ 149,00

Zetia

Price range: $ 51,00 through $ 394,00

Zetia is an effective medication specifically designed to help lower elevated cholesterol levels in the blood. This treatment works by targeting the small intestine to reduce the amount of cholesterol your body absorbs from food. It is primarily indicated for patients with high LDL, commonly referred to as “bad” cholesterol, to improve their overall lipid profile. The formula can be used alone or in conjunction with a healthy diet to manage primary hyperlipidemia effectively. Regular use of Zetia supports cardiovascular health by helping to maintain cholesterol within a healthy range.

Active substance: Ezetimibe
SKU: Zetia Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Zetia (ezetimibe) belongs to a class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol and related plant sterols. It is prescribed in the United States as an FDA-approved prescription medication to reduce elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary hyperlipidemia, used either as monotherapy or in combination with an HMG-CoA reductase inhibitor (statin).

The medication is supplied as a 10 mg oral tablet and is dispensed in accordance with applicable federal and state regulations requiring a prescription from a licensed healthcare provider. Understanding its pharmacological mechanisms, proper administration schedules, and safety considerations is essential for achieving optimal therapeutic outcomes.

Drug name Zetia
Active ingredient (INN) Ezetimibe
Therapeutic class Intestinal cholesterol absorption inhibitor
Dosage form Oral tablet (10 mg)
Route of administration Oral
Prescription status Prescription (Rx) only
Storage Store at 20°C to 25°C (68°F to 77°F)

Pharmacological Overview and Indications

How the drug works

The active component of Zetia, ezetimibe, localized at the brush border of the small intestine, inhibits the absorption of dietary and biliary cholesterol. Specifically, it targets the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter protein located in the enterocytes. By blocking intestinal cholesterol transport, Zetia decreases the delivery of intestinal cholesterol to the liver. This leads to a depletion of hepatic cholesterol stores and a subsequent upregulation of hepatic LDL receptors, resulting in increased clearance of LDL cholesterol from the circulation. Unlike plant stanols or bile acid sequestrants, Zetia does not alter the absorption of fat-soluble vitamins (A, D, E, K), triglycerides, or ethinyl estradiol.

Main uses

Zetia is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol, LDL-C, and Apo B in adult and pediatric patients (10 years of age and older) with primary hyperlipidemia, including heterozygous familial and non-familial hypercholesterolemia. It may be prescribed as monotherapy when statin therapy is considered inappropriate or not tolerated, or in combination with a statin when monotherapy fails to achieve target lipid parameters. Additional FDA-approved indications include combination therapy with a statin for Homozygous Familial Hypercholesterolemia (HoFH) and monotherapy for Homozygous Sitosterolemia (phytosterolemia). Clinical evaluation of off-label indications, such as non-alcoholic fatty liver disease (NAFLD), remains investigative and is explicitly categorized as off-label use not approved by the FDA.

What you may notice early on

Unlike rapid-acting medications, Zetia does not produce immediate symptomatic changes, as hyperlipidemia is typically an asymptomatic condition. Laboratory evaluations generally demonstrate measurable reductions in serum LDL-C levels within two weeks of initiating continuous daily treatment, with maximal therapeutic effect achieved by approximately four weeks. Patients should not expect perceptible physical sensations confirming drug activity; efficacy is monitored exclusively through periodic routine blood lipid panels ordered by the prescribing physician.

Dosing schedule

The recommended dosage of Zetia is 10 mg orally once daily. The tablet may be administered in the morning or evening, with or without food. When co-administered with a statin, Zetia may be taken at the same time as the statin, adhering to the dosing instructions of the co-administered agent. For patients receiving bile acid sequestrants (such as cholestyramine), Zetia must be administered either at least 2 hours before or at least 4 hours after the bile acid sequestrant to prevent impaired absorption. Dosage adjustments are not required for elderly patients or individuals with mild hepatic impairment or renal dysfunction.

What happens in the body

After oral administration, ezetimibe is rapidly absorbed and extensively conjugated in the small intestine and liver to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). Peak plasma concentrations of total ezetimibe occur within 1 to 2 hours for ezetimibe-glucuronide and 4 to 12 hours for unchanged ezetimibe. Concomitant food intake does not significantly affect the extent of absorption. Both ezetimibe and its glucuronide metabolite are highly bound to human plasma proteins (greater than 90%). The compound undergoes extensive enterohepatic recycling, contributing to a prolonged terminal elimination half-life of approximately 22 hours for both parent drug and active metabolite. Following oral administration of radiolabeled ezetimibe, approximately 78% of the dose is excreted in feces and 11% in urine over a 10-day collection period.

Safety Profile and Clinical Management

What not to combine

Concomitant administration of Zetia with specific pharmacological agents requires evaluation due to altered pharmacokinetics or additive adverse risks. Co-administration with fibrates, particularly gemfibrozil, increases total ezetimibe concentrations approximately 1.7-fold and increases the risk of cholelithiasis; concurrent use with gemfibrozil is generally not recommended. Cholestyramine decreases the mean area under the curve (AUC) of total ezetimibe by approximately 55%, necessitating separated administration times. Concomitant use with cyclosporine significantly increases total ezetimibe exposure (up to 3.4-fold to 12-fold increase), and cyclosporine concentrations may also increase; frequent monitoring of cyclosporine blood levels is required if combined. Caution is advised when co-administering with anticoagulants like warfarin, requiring routine international normalized ratio (INR) monitoring.

What side effects may occur

In clinical trials, Zetia was generally well tolerated, with an overall incidence of adverse reactions similar to placebo. As monotherapy, reported adverse events occurring at an incidence of 2% or greater and at a rate higher than placebo include upper respiratory tract infection, diarrhea, arthralgia, sinusitis, and pain in an extremity. When co-administered with a statin, common adverse effects include nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea, and back pain. Transaminase elevations (ALT and/or AST 3 or more times the upper limit of normal) occur more frequently when Zetia is combined with a statin (approximately 1.3%) compared to statin monotherapy (0.4%). Muscle-related side effects, including rare instances of myopathy or rhabdomyolysis, have been reported, primarily when prescribed concurrently with statin therapy.

Red flags

Patients receiving Zetia must be monitored for serious adverse reactions that require immediate medical intervention. Urgent healthcare attention should be sought if any of the following manifestations occur:

  • Signs of severe hypersensitivity, including swelling of the face, lips, tongue, or throat, severe rash, or difficulty breathing or swallowing.
  • Unexplained muscle pain, tenderness, or weakness, particularly when accompanied by malaise or fever, which may indicate myopathy or rhabdomyolysis.
  • Dark or tea-colored urine combined with severe muscle symptoms.
  • Symptoms suggestive of hepatic dysfunction, such as persistent nausea, unusual fatigue, yellowing of the skin or eyes (jaundice), abdominal pain in the upper right quadrant, or dark urine.
  • Severe abdominal pain radiating to the back, potentially indicating pancreatitis.

Important precautions

Zetia is contraindicated in patients with known hypersensitivity to ezetimibe or any inactive component of the tablet. When co-administered with a statin, all contraindications to that specific statin apply, including active liver disease or unexplained persistent elevations in hepatic transaminases. Zetia is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh classes B or C) due to increased systemic exposure. When combined with a statin in pregnant or nursing women, prescribers must account for the pregnancy category and lactation warnings of the co-prescribed statin, as statins are contraindicated during pregnancy. Hepatic function tests should be conducted at baseline and as clinically indicated when initiating combination therapy.

Food and alcohol interactions

Zetia can be taken with or without food, as lipid intake does not meaningfully alter its bioavailability or clinical efficacy. There are no direct interactions between ezetimibe and moderate alcohol consumption; however, excessive alcohol intake can increase the risk of hepatic toxicity, especially when Zetia is taken concurrently with a statin. Patients should discuss their alcohol consumption habits with their prescribing physician prior to initiating therapy.

Storage and expiration

Zetia tablets should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F) in accordance with USP regulations. The medication must be kept in its original container, tightly closed, and protected from excess moisture and heat. Do not store tablets in humid environments such as bathroom cabinets. Discard any medication that has passed its printed expiration date in accordance with local pharmaceutical disposal guidelines.

Common questions

What should be done if a daily dose of Zetia is missed?

If a dose of Zetia is missed, the patient should take the next scheduled dose at the regular time on the following day. Patients must not double the dose or take extra tablets to make up for a skipped dose, as maintaining a consistent daily 10 mg regimen is sufficient for ongoing cholesterol management.

Can Zetia be taken at the same time as a statin medication?

Yes, when prescribed as combination therapy, Zetia and a statin may be swallowed together at the same time of day, either in the morning or evening. However, patients must ensure they adhere to any specific timing recommendations associated with their specific statin agent as instructed by their prescriber.

Is routine blood testing required while taking Zetia?

Yes, routine liver function monitoring and periodic lipid panels are standard clinical practice. Blood tests allow the prescriber to evaluate therapeutic efficacy in lowering LDL cholesterol and to monitor hepatic enzyme levels, particularly when Zetia is taken in combination with a statin.

Does Zetia cause weight changes or affect blood pressure?

Clinical trials have shown that Zetia does not directly cause weight gain, weight loss, or changes in systemic blood pressure. Any changes in body weight or blood pressure during treatment are likely related to underlying lifestyle modifications, concurrent medications, or non-associated medical conditions.

Can Zetia be discontinued abruptly if cholesterol levels reach target goals?

Zetia should not be stopped without consulting the prescribing physician. Hyperlipidemia is a chronic condition, and stopping the medication typically results in serum cholesterol returning to baseline levels within several weeks. Treatment decisions must be managed under medical oversight.

In accordance with FDA requirements.

This overview is informational. For decisions about your treatment, consult a qualified healthcare professional.

Additional information
Dosage

10mg

Package

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία